FDA updates border controls for GLP-1 drug ingredients

The Food and Drug Administration published a major revision of its GLP-1 active-ingredient import alert on August 13, adding orforglipron products and expanding the documentation manufacturers may submit to establish compliance with federal quality requirements.

Import Alert 66-80 directs FDA field personnel to consider detaining foreign-sourced GLP-1 receptor agonist active pharmaceutical ingredients, or APIs, without first physically examining each shipment. Products from manufacturers on the alert’s Green List are excluded from that recommendation because FDA’s evaluation indicates that the listed facilities and products appear to comply with current good manufacturing practice requirements.

The update matters because it sharpens the agency’s control over raw ingredients entering a supply chain that expanded rapidly during shortages of approved semaglutide and tirzepatide products. It does not prohibit all GLP-1 ingredient imports, declare every unlisted shipment adulterated or create a new restriction on otherwise lawful compounding.

What changed

The revision adds orforglipron API from three manufacturers to the Green List and an orforglipron spray-dried dispersion drug-product intermediate from one manufacturer. It also adds a specific FDA product code for orforglipron and several broader hormone product codes.

Orforglipron requires a distinction that is easy to miss in discussions of this drug class. It activates the GLP-1 receptor but is a small molecule, not a peptide. FDA approved it as Foundayo for chronic weight management on April 1, 2026. Its appearance in an alert centered on GLP-1 APIs illustrates that the agency’s border policy follows pharmacologic and supply-chain categories rather than peptide chemistry alone.

Green List placement is not a blanket endorsement of a manufacturer, finished compounded product or commercial seller. It means only that the specified facility-product combination is excluded from the alert’s detention recommendation based on the evidence FDA evaluated. A listed API must still be used and distributed in compliance with the other laws applicable to the product.

Why FDA is scrutinizing the supply chain

FDA says it evaluated 48 GLP-1 API sites through inspections or remote regulatory assessments. The agency reported that 21% were noncompliant under the Federal Food, Drug, and Cosmetic Act because records showed manufacturing-practice deficiencies or because a firm did not answer an FDA records request on time. FDA also described a pattern in which some sites registered as GLP-1 API manufacturers, offered ingredients for import, declined records requests and then quickly deregistered.

The alert highlights a particular concern involving drugs compounded under section 503A. Although API manufacturers remain subject to current good manufacturing practice requirements, qualifying 503A compounders are exempt from those requirements. FDA’s position is that defects involving impurity control, potency or other properties of a bulk ingredient may therefore be less likely to be detected or controlled when the finished dosage form is compounded.

To seek Green List placement, a manufacturer may provide information identifying every physical production site and evidence of compliance. The revised guidance gives examples: certificates of analysis for the most recent 10 lots, container labels, customer information, release specifications and testing methods, scientific justification for impurity and potency limits, and stability-testing protocols and results.

What the alert does not establish

Detention without physical examination is an enforcement screening mechanism based on the appearance of a violation. The alert is guidance to FDA personnel, not a clinical study, a product recall or proof that a particular patient was harmed. It also does not evaluate whether compounded GLP-1 products are effective.

FDA separately cautions that compounded drugs do not undergo its premarket review for safety, effectiveness and quality. The practical meaning of the new revision is narrower: manufacturers seeking access to the U.S. GLP-1 ingredient market now have a more explicit roadmap for demonstrating quality compliance, while shipments outside the Green List remain exposed to detention at the border.